Monday, July 22, 2013

BULLISH ON IOC!! VERY UNDERVALUED!! InterOil's (IOC) New CEO Hits the Ground Running - Raymond James

Raymond James Analyst  Paval Molchanov reiterated an outperform Rating for IOC at 100!! http://www.streetinsider.com/Analyst+Comments/InterOils+%28IOC%29+New+CEO+Hits+the+Ground+Running+-+Raymond+James/8493163.html InterOil Enters Into a Combined $350.0 Million Refinery Working Capital Facility

PORT MORESBY,Papua New Guinea andHOUSTONJuly 17, 2013 /CNW/ - InterOil Corporation (NYSE:IOC) (POMSoX:IOC) announced that IOC and its subsidiaries, EP InterOil and InterOil Limited, have entered into a $350.0 millionworking capital structured facility arranged by BNP Paribas (BNP), also acting as lead manager, to replace the existing $240.0 millionbilateral working capital facility with BNP.
Out of the $350.0 million$270.0 million will be a syndicated secured working capital facility with the support of five banking partners, namely: BNP,Australia and New Zealand Banking Group Limited (ANZ), Natixis, Intesa Sanpaolo (Intesa), and Bank South Pacific Limited (BSP). In addition, BNP will also be providing an $80.0 millionbilateral non-recourse discounting facility.
The secured facility is to support the operational requirements of the Napa Napa Refinery inPapua New Guinea (PNG). It will be secured by InterOil's rights, title and interest in inventory and working capital of the Napa Napa Refinery.
Credit portion of the facility bears interest at LIBOR plus 3.75%. Funding is subject to Bank ofPapua New Guinea approval on the granting of PNG security over refinery assets, and other standard closing conditions.
InterOil is pleased to have the support and confidence of longstanding banking partners. Collin Visaggio, InterOil's CFO remarked, "We are delighted to have strengthened our banking relationship with BNP who have led our existing working capital facility since 2004, and broadening our relationships with existing financiers like ANZ, BSP, and new syndicate partners Natixis and Intesa. The financing will assist with the ongoing operational activities of the refinery, which has experienced consistent growth over the past 5 years."
About InterOilInterOil Corporation is developing a vertically integrated energy business whose primary focus isPapua New Guinea and the surrounding region. InterOil's assets consist of petroleum licenses covering about 3.9 million acres, an oil refinery, and retail and commercial distribution facilities, all located in Papua New Guinea. InterOil's common shares trade on the NYSE in US dollars.
Investor Contacts for InterOil
Wayne Andrews
Meg LaSalle
Vice President Capital Markets
Investor Relations Coordinator
The Woodlands, TX USA
The Woodlands, TX USA
Phone: +1-281-292-1800
Phone: +1-281-292-1800
Forward Looking StatementsThis press release includes "forward-looking statements" as defined in United States federal and Canadian securities laws. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the InterOil expects, believes or anticipates will or may occur in the future are forward-looking statements, including in particular, the use of the funds from the loan facility, and closing of the loan facility. These statements are based on certain assumptions made by the Company based on its experience and perception of current conditions, expected future developments and other factors it believes are appropriate in the circumstances, including the terms of the loan facility. No assurances can be given however, that these events will occur. Actual results will differ, and the difference may be material and adverse to the Company and its shareholders. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause our actual results to differ materially from those implied or expressed by the forward-looking statements. Some of these factors include the risk factors discussed in the Company's filings with the Securities and Exchange Commission and on SEDAR, including but not limited to those in the Company's Annual Report for the year endedDecember 31, 2011 on Form 40-F and its Annual Information Form for the year ended December 31, 2011. In particular, there is no established market for natural gas or gas condensate in Papua New Guinea and no guarantee that gas or gas condensate from the Elk and Antelope fields will ultimately be able to be extracted and sold commercially.
Investors are urged to consider closely the disclosure in the Company's Form 40-F, available from us at www.interoil.com or from the SEC at www.sec.gov and its Annual Information Form available on SEDAR at www.sedar.com.
SOURCE: InterOil Corporation
http://www.interoil.com
Copyright CNW Group 2013 
Source: Canada Newswire (July 17, 2013 - 7:30 AM EDT) 


This Natural Gas Play Undervalued?

IOCInterOil Cor
CAPS Rating1/5 Stars
Up $85.63 $7.73 (9.92%)

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.
Whenever a company is in the midst of a major transformation, there are lots of risks along the way that could potentially turn sour. So, as investors, we try to mitigate this risk by digging deep into these respective companies so we have as clear a picture as possible. InterOil (NYSE: IOC  )  has flown under the radar for a while, but it has big plans to capture the Asian natural gas market. Is InterOil an unspoken gem that the market is undervaluing? Or are its ambitious plans too big for the company to handle? Let's take a better look at these questions to get a clearer picture.
Undervalued?
One of the reasons InterOil doesn't get much attention is its location. The entirety of the company's natural gas assets are on the island nation of Papua New Guinea. This doesn't make them any less valuable, though. The company owns leasing rights to almost 4 million gross acres in the country. A study done by GLJ Petroleum Consultants estimates that the company's acreage has as much as 6.0 trillion cubic feet of recoverable reserves.
If the company's estimates are correct, it is quite possibly one of the most undervalued assets around. This would give the company a market cap value of about $0.62 per thousand cubic feet equivalent of reserves. Compare that with Linn Energy's  (NASDAQ: LINE  ) 4.7 Tcfe of proven reserves and market cap value of about $1.87 per thousand cubic feet equivalent of reserves. 
Here's the catch: Not all of InterOil's 6.0 Tcfe are proven. Since its inception, InterOil has spudded 14 exploratory wells on all of its its holdings. While some of the initial production rates on these wells have been exceptionally high, they were immediately shut in. It is difficult to determine metrics such as the decline rate and the estimated ultimate recovery for these wells without their having produced for some time. It's also hard to determine the full potential of a 4 million-acre site based on a dozen exploratory wells and seismic mapping. While the potential for something great is there, it's still too early to give a final verdict on Interoil's prospects.
Overreaching?
InterOil currently has two business segments that generate revenue for the company: its midstream and refining segment, and its retail and marketing operations. So far, almost all of the profits from these segments have gone into exploration and production. It has also used the sale of interest stakes in some of its upstream assets to help finance both its upstream operations and its initial efforts to build an LNG export facility. Unfortunately for the company, the proceeds from these operations aren't enough to fund its plans at a very rapid pace. This is why the company has for quite some time sought out partners to execute this strategy. It found two last year. Both the Papua New Guinean government and Colombian E&P companyPacific Rubiales took minority interest stakes in some of its exploration fields.
Still, this isn't quite enough. The company will need a large injection of capital to expand its exploration and production capacity, build out a pipeline network to deliver gas from its wells to its export facility, and build the LNG export facility itself. InterOil hopes to have LNG facility up and running in a three- to five-year time frame. One note of promise on this front, though, is that the company has received several bids from companies to be the partner on the export facility. Investors can only hope that it chooses a partner with deep pockets. ExxonMobil's (NYSE: XOM  )  own LNG facility in PNG has gone over budget several times. When it is completed, Exxon estimates that the project will have cost around $19 billion.
That's not to say InterOil's vision is impossible, but it will be very difficult and it will take several years to play out.
What a Fool believes
There are certainly some signs coming from InterOil that show promise for the company, but at the same time the company will need lots of capital, help, and time to fully execute its strategy. One concern the company will run into is fierce competition for Asian LNG exports. By the time the InterOil hopes to have its LNG facility up and running, several LNG facilities will be in operation:
  • Exxon's PNG facility will have the capacity to move 6.9 million tons of LNG per year and will be ready by the end of 2014.
  • There are 8 LNG export facilities either in operation or under construction in Australia. The headliner of these facilities is the 9-million-ton-per-year facility in Queensland.  ConocoPhillips (NYSE: COP  ) , the operator of this future facility, expects to send its first shipment in 2015.
  • Canada's National Energy Board recently approved the first LNG export facility in British Columbia. This project, co-owned by Chevron (NYSE: CVX  ) and Apache (NYSE:APA  ) , will start with total capacity of 5 million tons per year, with a potential to expand to 10 million. The partners expect this facility to be operational by 2016.
By going up against such big players in the energy space with very deep pockets, InterOil could find the LNG export market much more difficult than originally anticipated.
For investors who are patient and have a high tolerance for risk, then perhaps InterOil should be on your watchlist. For someone looking for a safer investment in the energy space, then a company like National Oilwell Varco is hard to beat. It has almost 60% of the oil services market share and is positioned well to take advantage of markets both in North America and abroad. To help determine whether this company is a nice fit for your portfolio, check out our premium research report with in-depth analysis on whether NOV is a buy today. For instant access to this valuable investor's resource, simply click here now and claim your copy today.
The Fool just turned 20; our paying members are getting rich...
And we're in a mood to celebrate. That's why our top stock pickers (just ranked #1, #2, and #3 over the last 5 years according to an industry watchdog) are about to roll out the next generation of Motley Fool signature stock picks. We're talking about what could be the next Amazon (1,700% gains)... Priceline (up 3,300%)... or Netflix (up over 1,500%)...

In fact, we believe so strongly in all this, we're plunking down our own company money on a few of these stocks! And we want to invite you along to see it all - FREE, no strings attached. Just enter your email address, and we'll be in touch.

Shire plc (NASDAQ: SHPG [FREE Stock Trend Analysis]), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse^® (lisdexamfetamine dimesylate) Capsules, (CII) as a maintenance treatment in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Vyvanse is currently approved as a maintenance treatment in adults with ADHD. With this new approval, Vyvanse becomes the only stimulant approved for maintenance treatment in children, adolescents, and adults (patients ages 6 and above) with ADHD. Jefferies reiterated its Buy rating on Shire PLC (NASDAQ: SHPG [FREE Stock Trend Analysis]), but lowered its price target from $117.00 to $112.00/ Barclays Upgrades Shire Plc to Overweight on Growth Profile

UPDATE: Shire's Vyvanse Approved in US for Children with ADHD

Shire plc (NASDAQ: SHPG [FREE Stock Trend Analysis]), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse^® (lisdexamfetamine dimesylate) Capsules, (CII) as a maintenance treatment in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Vyvanse is currently approved as a maintenance treatment in adults with ADHD. With this new approval, Vyvanse becomes the only stimulant approved for maintenance treatment in children, adolescents, and adults (patients ages 6 and above) with ADHD.
The approval is based on results from a 32-week study: 26 weeks of open-label treatment with Vyvanse followed by a 6-week randomized withdrawal phase. The study was designed to evaluate the continued efficacy of Vyvanse in children and adolescents (aged 6 to 17 years). A significantly lower proportion of treatment failures occurred among Vyvanse patients (15.8%) compared to placebo (67.5%) at end point of the randomized withdrawal period, showing that significantly more patients treated with Vyvanse maintained ADHD symptom control compared with placebo.
Vyvanse is a Schedule II controlled substance. CNS Stimulants (amphetamines and methylphenidate-containing products) have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence.
To evaluate the efficacy of Vyvanse for maintenance treatment in children and adolescents with ADHD, Shire elected to conduct a double-blind, placebo-controlled, randomized withdrawal clinical trial. In this design, patients who respond to a treatment are randomized to continue receiving that treatment or placebo. Using the proportion of patients experiencing symptom relapse as a primary outcome, this type of study in patients with ADHD can be used to demonstrate long-term efficacy in lieu of conducting a long-term, placebo-controlled, parallel-group study. The utility of this design is that the period of placebo exposure, with the potential for worsening of ADHD symptoms, is relatively short.
The double-blind, placebo-controlled, randomized withdrawal study was conducted in 276 children and adolescents aged 6 to 17 with ADHD. Of these patients, 236 participated in a preceding study and 40 directly enrolled. The study consisted of 4 phases:
o 4-week, open-label, dose-optimization phase in which patients received Vyvanse 30 mg/day, 50 mg/day, or 70 mg/day. Eligible subjects started on Vyvanse 30 mg/day and could be titrated in weekly increments of 20 mg until an optimal dose was reached (up to a maximum of 70 mg/day) o 20-week, open-label, maintenance phase o 2-week, open-label, fixed-dose phase in which patients were discontinued if they required further dose adjustments, experienced unacceptable tolerability, or had an Attention-Deficit/Hyperactivity Disorder Rating Scale, Version IV (ADHD-RS-IV) total score >22 or Clinical Global Impression Severity (CGI-S) score ≥3. Patients who maintained treatment response entered the randomized withdrawal phase. o 6-week, double-blind, randomized withdrawal phase in which patients either received ongoing treatment with the same dose of Vyvanse (N=78) or were switched to placebo (N=79).
The primary outcome measure was the proportion of patients who met criteria for relapse of ADHD symptoms (treatment failure) at end point during the double-blind, randomized withdrawal phase. The end point measurement was defined as the last post-randomization treatment week at which a valid ADHD-RS Total Score and CGI-S were observed. Treatment failure was defined as a ≥50% increase (worsening) in the ADHD-RS Total Score and a ≥2-point increase in the CGI-S score compared to scores at entry into the double-blind, randomized withdrawal phase. On the primary end point, significantly fewer patients met criteria for symptom relapse with Vyvanse (15.8%) versus placebo (67.5%) (P<.001).
During the 26-week open-label phase, 12 patients (4.3%) reported serious adverse events (SAEs), and 45 patients (16.3%) reported treatment-emergent adverse events (TEAEs) that resulted in Vyvanse discontinuation. During the randomized withdrawal phase, no SAEs were reported in the Vyvanse group, no patients in the Vyvanse group discontinued due to a TEAE, and 1 patient in the placebo group discontinued due to a TEAE. In addition, 39.7% (31/78) of patients receiving Vyvanse and 25.3% (20/79) on placebo reported TEAEs. The most common TEAEs (≥2%) reported in the Vyvanse treatment group during the randomized withdrawal phase included nasopharyngitis, headache, abdominal pain upper, oropharyngeal pain, decreased appetite, vomiting, weight decrease, abdominal pain, accidental overdose, aggression, cough, nausea and rhinitis.
Patients receiving Vyvanse demonstrated a moderate increase in mean pulse rate (~5 beats per minute) and blood pressure (~2 mm Hg systolic and diastolic blood pressure) between baseline and end point of the randomized withdrawal period. Patients treated with Vyvanse experienced a mean decrease in body weight of about 2 kg during the 26-week open-label period. Mean weight tended to increase in patients who switched to placebo during the randomized withdrawal phase. There were no deaths reported during the trial. The safety profile seen in this study was consistent with that of other studies of Vyvanse, and no new clinically relevant safety signals were associated with abrupt discontinuation of Vyvanse.

Read more: http://www.benzinga.com/news/13/05/3549758/update-shires-vyvanse-approved-in-us-for-children-with-adhd#ixzz2Zo8Vo8lfUPDATE: Deutsche Bank Raises PT on Shire Following Investor Dinner

In a report published Friday, Deutsche Bank analyst Greg Poole reiterated a Buy rating on Shire (NASDAQ: SHPG [FREE Stock Trend Analysis]), and raised the price target from $101.00 to $109.00.
In the report, Deutsche Bank noted, “We hosted a small investor dinner with Shire management this week, where new CEO Dr. Flemming Ornskov offered a comprehensive, updated view of the company – having now been at the company for nearly six months. In summary, while Shire faces a number of challenges, we again like what we heard from the new CEO. Dr. Ornskov's highest priority is to enhance Shire's long term growth rate, by 1) maximizing its current product portfolio, 2) marshalling resources behind the most promising pipeline opportunities, and 3) executing ‘very smart' business development and M&A.”


Read more: http://www.benzinga.com/analyst-ratings/analyst-color/13/05/3637392/update-deutsche-bank-raises-pt-on-shire-following-invest#ixzz2Zo8Clb6F